Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARTELO BIOSCIENCES, INC.ARTL · Entity 8413 | Director | July 17, 2026 | July 21, 2026 |
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | Director | November 29, 2024 | December 03, 2024 |
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | Director | June 05, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARTELO BIOSCIENCES, INC.
Report date July 17, 2026 · Filed July 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2036-07-17 | Direct | 136 |
Reported balance
After 2026-07-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-17 · Grant · Acquired 136 · Balance 136 F1: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026.
HALOZYME THERAPEUTICS, INC.
Report date November 29, 2024 · Filed December 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 183,035 |
Reported balance
After 2024-11-29 transaction · row 1
1 source rowRow 1 · 2024-11-29 · Gift · Disposed 10,470 · Balance 183,035 F1: Represents a bona fide gift to charity. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a bona fide gift to charity.
SUTRO BIOPHARMA, INC.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.09 · Expires 2036-06-05 | Direct | 10,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 10,000 · Balance 10,000 F1: The option shall vest, subject to the reporting person's provision of service to the issuer on each vesting date, as to 8.33% of the total award monthly, with the first tranche vesting on July 5, 2026, and the award shall be fully vested and exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 5, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest, subject to the reporting person's provision of service to the issuer on each vesting date, as to 8.33% of the total award monthly, with the first tranche vesting on July 5, 2026, and the award shall be fully vested and exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 5, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 17, 2026 Filed Jul 21, 2026 22:31 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 136 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001640334-26-001231 · form4.xml · derivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136 Underlying: Common Stock · 136 shares Expires 2036-07-17 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 20:12 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $26.09 | $0.00 |
DisclosureSEC source: 0001236537-26-000002 · form4-06092026_080655.xml · derivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-06-05 F1 · derivative.exercise_date: The option shall vest, subject to the reporting person's provision of service to the issuer on each vesting date, as to 8.33% of the total award monthly, with the first tranche vesting on July 5, 2026, and the award shall be fully vested and exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 5, 2027. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 21:57 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Options (right to buy) · Derivative | 292 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001640334-26-000199 · form4.xml · derivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292 Underlying: Common Stock · 292 shares Expires 2036-01-30 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean January 30, 2026. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 22:03 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001236537-25-000008 · form4-12292025_101213.xml · derivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2035-12-23 F1 · derivative.exercise_date: The option shall vest as to 16.67% of the total award monthly, subject to the reporting person's continued service to the issuer on each vesting date, with the first tranche vesting on January 23, 2026. Read SEC document |
| October 28, 2025 Filed Oct 31, 2025 01:30 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | ConversionConvertible Promissory Note · Derivative | Not disclosed | $110,843.00 Strike: $3.40 | $110,843.00 |
DisclosureSEC source: 0001640334-25-001925 · form4.xml · derivative · entry 4 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · Not disclosed shares Expires 2026-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant"). F2 · kind: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock. F1 · derivative.underlying_shares: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant"). F2 · derivative.underlying_shares: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock. Read SEC document |
| October 28, 2025 Filed Oct 31, 2025 01:30 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | ConversionWarrant (right to buy) · Derivative | 70,376 | Not disclosed Strike: $3.40 | Not disclosed |
DisclosureSEC source: 0001640334-25-001925 · form4.xml · derivative · entry 3 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,376 Underlying: Common Stock · 70,376 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock. F1 · kind: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant"). F2 · price: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock. F1 · price: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant"). Read SEC document |
| October 28, 2025 Filed Oct 31, 2025 01:30 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | ConversionWarrant (right to buy) · Derivative | 38,346 | Not disclosed Strike: $6.24 | Not disclosed |
DisclosureSEC source: 0001640334-25-001925 · form4.xml · derivative · entry 2 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,346 Underlying: Common Stock · 38,346 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock. F1 · kind: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant"). F1 · price: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant"). F2 · price: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock. Read SEC document |
| October 28, 2025 Filed Oct 31, 2025 01:30 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | ConversionConvertible Promissory Note · Derivative | Not disclosed | $140,000.00 | $140,000.00 |
DisclosureSEC source: 0001640334-25-001925 · form4.xml · derivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · Not disclosed shares Expires 2025-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant"). F2 · derivative.exercise_price: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock. F2 · kind: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock. F1 · kind: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant"). F2 · derivative.underlying_shares: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock. F1 · derivative.underlying_shares: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant"). Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 12:15 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | PurchaseCommon Stock | 50,000 | $0.80 | $39,950.00 |
DisclosureSEC source: 0001236537-25-000006 · form4-10162025_121046.xml · nonDerivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:12 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001415889-25-016468 · form4-06102025_080602.xml · derivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-06-06 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 6, 2025, with 100% of the total shares vested and exercisable on the earlier of the date of the issuer's 2026 annual stockholders meeting or June 6, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| May 01, 2025 Filed May 5, 2025 21:21 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | PurchaseConvertible Promissory Note · Derivative | Not disclosed | $140,000.00 | $140,000.00 |
DisclosureSEC source: 0001640334-25-000788 · form4.xml · derivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · Not disclosed shares Expires 2025-10-28 F1 · derivative.exercise_price: On or about May 1, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") with the Reporting Person, pursuant to which the Issuer issued a convertible note (the "Note") to the Reporting Person. The Notes will accrue interest at a rate of 12% per annum, which will adjust to 20% upon an Event of Default (as defined in the Note). All unpaid principal, together with any then unpaid and accrued interest and other amounts payable thereunder, shall be due and payable on October 28, 2025 (the "Maturity Date"). F2 · derivative.exercise_price: At the Maturity Date, the Reporting Person may (at the Reporting Person's sole option) convert all of that certain unpaid portion of principal and accrued interest of the Reporting Person's Note into shares of the Issuer's common stock ("Common Stock") (the "Voluntary Conversion"), specifically into that number of shares of Common Stock (the "Converted Shares") equal to the unpaid principal balance and any accrued interest of each Note divided by $1.29. The amount of principal balance and any accrued interest of the Note convertible pursuant to the Voluntary Conversion shall be the number of Converted Shares multiplied by $1.04 (the "Minimum Price"). Should the Reporting Person not elect Voluntary Conversion, such portion of the unpaid principal balance and any accrued interest of the Note subject to Voluntary Conversion shall be immediately due and payable in cash. F3 · derivative.exercise_price: At the Maturity Date, that portion of the unpaid principal balance and any accrued interest of the Note not subject to the Voluntary Conversion shall be automatically converted into a warrant to purchase shares of the Issuer's Common Stock (the "Warrant") at a conversion price of $0.125 per share issuable pursuant to the Warrant (the "Automatic Conversion"). The exercise price of such Warrant for each Warrant Share shall be equal to the Minimum Price. F1 · derivative.underlying_shares: On or about May 1, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") with the Reporting Person, pursuant to which the Issuer issued a convertible note (the "Note") to the Reporting Person. The Notes will accrue interest at a rate of 12% per annum, which will adjust to 20% upon an Event of Default (as defined in the Note). All unpaid principal, together with any then unpaid and accrued interest and other amounts payable thereunder, shall be due and payable on October 28, 2025 (the "Maturity Date"). F2 · derivative.underlying_shares: At the Maturity Date, the Reporting Person may (at the Reporting Person's sole option) convert all of that certain unpaid portion of principal and accrued interest of the Reporting Person's Note into shares of the Issuer's common stock ("Common Stock") (the "Voluntary Conversion"), specifically into that number of shares of Common Stock (the "Converted Shares") equal to the unpaid principal balance and any accrued interest of each Note divided by $1.29. The amount of principal balance and any accrued interest of the Note convertible pursuant to the Voluntary Conversion shall be the number of Converted Shares multiplied by $1.04 (the "Minimum Price"). Should the Reporting Person not elect Voluntary Conversion, such portion of the unpaid principal balance and any accrued interest of the Note subject to Voluntary Conversion shall be immediately due and payable in cash. F3 · derivative.underlying_shares: At the Maturity Date, that portion of the unpaid principal balance and any accrued interest of the Note not subject to the Voluntary Conversion shall be automatically converted into a warrant to purchase shares of the Issuer's Common Stock (the "Warrant") at a conversion price of $0.125 per share issuable pursuant to the Warrant (the "Automatic Conversion"). The exercise price of such Warrant for each Warrant Share shall be equal to the Minimum Price. Read SEC document |
| December 20, 2024 Filed Dec 23, 2024 21:02 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 1,750 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001640334-24-001935 · form4.xml · derivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,750 Underlying: Common Stock · 1,750 shares Expires 2034-12-20 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean December 20, 2024. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 21:05 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GiftCommon Stock | 10,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028062 · form4-12032024_091236.xml · nonDerivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,035 F1 · kind: Represents a bona fide gift to charity. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:26 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001415889-24-016219 · form4-06102024_080611.xml · derivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-06-06 F1 · derivative.exercise_date: The option vests as to 8.33% of the total award monthly, commencing July 6, 2024, with 100% of the award vested and exercisable on the earlier of the date of the issuer's 2025 annual stockholders meeting or June 6, 2025, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 22:05 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 8,804 | $0.00 Strike: $38.46 | $0.00 |
DisclosureSEC source: 0001415889-24-011698 · form4-04292024_100436.xml · derivative · entry 2 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,804 Underlying: Common Stock · 8,804 shares Expires 2034-04-25 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 22:05 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 6,501 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-011698 · form4-04292024_100436.xml · nonDerivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,505 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 23:09 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 1,083 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0001640334-24-000329 · primary_doc.xml · derivative · entry 12 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,083 Underlying: Common Stock · 1,083 shares Expires 2033-08-04 F2 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F8 · derivative.exercise_date: Pursuant to the Offer, and subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the first anniversary of the Amendment Date, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Amendment Date (or, if there is no such day, the last day of the month). "Amendment Date" shall mean February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 23:09 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 667 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0001640334-24-000329 · primary_doc.xml · derivative · entry 11 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667 Underlying: Common Stock · 667 shares Expires 2033-06-30 F2 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F8 · derivative.exercise_date: Pursuant to the Offer, and subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the first anniversary of the Amendment Date, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Amendment Date (or, if there is no such day, the last day of the month). "Amendment Date" shall mean February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 23:09 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 667 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0001640334-24-000329 · primary_doc.xml · derivative · entry 10 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667 Underlying: Common Stock · 667 shares Expires 2032-06-24 F2 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F8 · derivative.exercise_date: Pursuant to the Offer, and subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the first anniversary of the Amendment Date, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Amendment Date (or, if there is no such day, the last day of the month). "Amendment Date" shall mean February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 23:09 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 667 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0001640334-24-000329 · primary_doc.xml · derivative · entry 9 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667 Underlying: Common Stock · 667 shares Expires 2031-07-16 F2 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F8 · derivative.exercise_date: Pursuant to the Offer, and subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the first anniversary of the Amendment Date, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Amendment Date (or, if there is no such day, the last day of the month). "Amendment Date" shall mean February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 23:09 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 10,634 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0001640334-24-000329 · primary_doc.xml · derivative · entry 8 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,634 Underlying: Common Stock · 10,634 shares Expires 2031-02-12 F2 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F8 · derivative.exercise_date: Pursuant to the Offer, and subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the first anniversary of the Amendment Date, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Amendment Date (or, if there is no such day, the last day of the month). "Amendment Date" shall mean February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 23:09 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 1,767 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0001640334-24-000329 · primary_doc.xml · derivative · entry 7 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,767 Underlying: Common Stock · 1,767 shares Expires 2029-08-29 F2 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F8 · derivative.exercise_date: Pursuant to the Offer, and subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the first anniversary of the Amendment Date, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Amendment Date (or, if there is no such day, the last day of the month). "Amendment Date" shall mean February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 23:09 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | Disposition to issuerStock Option (right to buy) · Derivative | 1,083 | Not disclosed Strike: $2.01 | Not disclosed |
DisclosureSEC source: 0001640334-24-000329 · primary_doc.xml · derivative · entry 6 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,083 shares Expires 2033-08-04 F2 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F7 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean August 4, 2023. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 23:09 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | Disposition to issuerStock Option (right to buy) · Derivative | 667 | Not disclosed Strike: $1.99 | Not disclosed |
DisclosureSEC source: 0001640334-24-000329 · primary_doc.xml · derivative · entry 5 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 667 shares Expires 2033-06-30 F2 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F6 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan (the "Plan")) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean June 30, 2023. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 23:09 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | Disposition to issuerStock Option (right to buy) · Derivative | 667 | Not disclosed Strike: $4.89 | Not disclosed |
DisclosureSEC source: 0001640334-24-000329 · primary_doc.xml · derivative · entry 4 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 667 shares Expires 2032-06-24 F5 · derivative.exercise_price: This option was granted on June 24, 2022 and was previously reported as covering 10,000 shares at an exercise price of $0.326 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. F2 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F5 · derivative.underlying_shares: This option was granted on June 24, 2022 and was previously reported as covering 10,000 shares at an exercise price of $0.326 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 23:09 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | Disposition to issuerStock Option (right to buy) · Derivative | 667 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001640334-24-000329 · primary_doc.xml · derivative · entry 3 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 667 shares Expires 2031-07-16 F4 · derivative.exercise_price: This option was granted on July 16, 2021 and was previously reported as covering 10,000 shares at an exercise price of $1.00 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. F2 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F4 · derivative.underlying_shares: This option was granted on July 16, 2021 and was previously reported as covering 10,000 shares at an exercise price of $1.00 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 23:09 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | Disposition to issuerStock Option (right to buy) · Derivative | 10,634 | Not disclosed Strike: $39.90 | Not disclosed |
DisclosureSEC source: 0001640334-24-000329 · primary_doc.xml · derivative · entry 2 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,634 shares Expires 2031-02-12 F3 · derivative.exercise_price: This option was granted on February 12, 2021 and was previously reported as covering 159,500 shares at an exercise price of $2.66 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. F2 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F3 · derivative.underlying_shares: This option was granted on February 12, 2021 and was previously reported as covering 159,500 shares at an exercise price of $2.66 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 23:09 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | Disposition to issuerStock Option (right to buy) · Derivative | 1,767 | Not disclosed Strike: $29.85 | Not disclosed |
DisclosureSEC source: 0001640334-24-000329 · primary_doc.xml · derivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,767 shares Expires 2029-08-29 F1 · derivative.exercise_price: This option was granted on August 29, 2019 and was previously reported as covering 26,500 shares at an exercise price of $1.99 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. F2 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer). F1 · derivative.underlying_shares: This option was granted on August 29, 2019 and was previously reported as covering 26,500 shares at an exercise price of $1.99 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022. Read SEC document |
| August 04, 2023 Filed Aug 8, 2023 20:58 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 1,083 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001640334-23-001492 · form4.xml · derivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,083 Underlying: Common Stock · 1,083 shares Expires 2033-08-04 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean August 4, 2023. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 18:05 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 667 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001640334-23-001200 · form4.xml · derivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667 Underlying: Common Stock · 667 shares Expires 2033-06-30 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean June 30, 2023. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 22:38 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.12 | $0.00 |
DisclosureSEC source: 0001209191-23-036471 · doc4.xml · derivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 8, 2023, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2024 annual stockholders meeting or June 8, 2024, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| May 05, 2023 Filed May 9, 2023 22:21 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 11,371 | $0.00 Strike: $31.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007692 · form4-05092023_100523.xml · derivative · entry 2 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,371 Underlying: Common Stock · 11,371 shares Expires 2033-05-05 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 05, 2023 Filed May 9, 2023 22:21 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 8,065 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007692 · form4-05092023_100523.xml · nonDerivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,004 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 22:11 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GiftCommon Stock | 9,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-011512 · form4-11172022_101138.xml · nonDerivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,939 F1 · kind: Represents a bona fide gift to charity. Read SEC document |
| June 24, 2022 Filed Jun 27, 2022 21:20 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001640334-22-001363 · form4.xml · derivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-06-24 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean June 24, 2022. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:07 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 18,500 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001209191-22-035209 · doc4.xml · derivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2032-06-05 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 6, 2022, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2023 annual stockholders meeting or June 6, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| May 05, 2022 Filed May 7, 2022 00:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units | 6,206 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-002910 · edgar.xml · nonDerivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,189 F1 · shares: Represents annual restricted stock unit grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2023 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| November 05, 2021 Filed Nov 5, 2021 21:59 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 12,548 | $40.77 | $511,581.96 |
DisclosureSEC source: 0001179110-21-009910 · edgar.xml · nonDerivative · entry 2 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,983 F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $40.622 to $41.04. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 05, 2021 Filed Nov 5, 2021 21:59 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 19,452 | $40.13 | $780,530.95 |
DisclosureSEC source: 0001179110-21-009910 · edgar.xml · nonDerivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,531 F1 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.59 to $40.57. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 16, 2021 Filed Jul 26, 2021 20:33 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001640334-21-001686 · form4.xml · derivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-07-16 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 16, 2021. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 21:04 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 18,500 | $0.00 Strike: $18.21 | $0.00 |
DisclosureSEC source: 0001209191-21-038685 · doc4.xml · derivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2031-06-02 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 3, 2021, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2022 annual stockholders meeting or June 3, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 00:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units | 5,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-004973 · edgar.xml · nonDerivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,983 F1 · shares: Represents annual restricted stock unit grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2022 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 22:14 UTC | ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 | GrantStock Option (right to buy) · Derivative | 159,500 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001640334-21-000385 · form4.xml · derivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,500 Underlying: Common Stock · 159,500 shares Expires 2031-02-12 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan) through each such applicable vesting date, fifty percent (50%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and fifty percent (50%) of the shares subject to the option shall vest on the two (2) year anniversary of the Vesting Commencement Date, such that the option shall be fully vested on the two (2) year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean February 12, 2021. Read SEC document |
| September 14, 2020 Filed Sep 14, 2020 21:33 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GiftCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-009727 · edgar.xml · nonDerivative · entry 2 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,753 F2 · kind: Represents a bona fide gift to a charitable organization. Read SEC document |
| September 11, 2020 Filed Sep 14, 2020 21:33 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 32,000 | $27.06 | $865,792.00 |
DisclosureSEC source: 0001179110-20-009727 · edgar.xml · nonDerivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,753 F1 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $26.95 to $27.16. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 21:28 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $9.83 | $0.00 |
DisclosureSEC source: 0001209191-20-035030 · doc4.xml · derivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-06-04 F1 · derivative.exercise_date: The option is fully vested on June 5, 2021, subject to the reporting person's provision of service to the issuer on the vesting date. Read SEC document |
| April 30, 2020 Filed May 1, 2020 23:14 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 8,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005380 · edgar.xml · nonDerivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,753 F1 · shares: Represents annual restricted stock grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) April 30, 2021 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 24, 2019 Filed Jun 26, 2019 20:52 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 23,076 | $0.00 Strike: $11.68 | $0.00 |
DisclosureSEC source: 0001209191-19-039123 · doc4.xml · derivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,076 Underlying: Common Stock · 23,076 shares Expires 2029-06-24 F1 · derivative.exercise_date: The option vests as to 1/36th of the total shares monthly, beginning on July 24, 2019, with 100% of the total shares vested and exercisable on June 24, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| May 02, 2019 Filed May 3, 2019 20:20 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 12,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005508 · edgar.xml · nonDerivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,924 F1 · shares: Represents annual restricted stock grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 2, 2020 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| December 07, 2018 Filed Dec 10, 2018 21:19 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GiftCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-013625 · edgar.xml · nonDerivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,751 F1 · kind: Represents a bona fide gift to a charitable organization. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.